| Literature DB >> 19525183 |
Jeanette M Waller1, John C Moretto, Kevin B Knopf.
Abstract
Bortezomib has shown significant efficacy in the treatment of patients with relapsed multiple myeloma (MM) and is generally well tolerated. We report a 65-year-old male patient undergoing bortezomib therapy for MM who, with the addition of liposomal doxorubicin, presented with severe paralytic ileus, peripheral neuropathy, pruritic rash, and testicular pain. Each of these toxicities was temporally related to the bortezomib-based therapy and the administration of concomitant liposomal doxorubicin. Herein, we discuss the patient's course and briefly review the literature on these bortezomib combination-related toxicities.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19525183 DOI: 10.3816/CLM.2009.n.051
Source DB: PubMed Journal: Clin Lymphoma Myeloma ISSN: 1557-9190